These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38272562)

  • 1. Inhibiting PLA2G7 reverses the immunosuppressive function of intratumoral macrophages and augments immunotherapy response in hepatocellular carcinoma.
    Zhang F; Liu W; Meng F; Jiang Q; Tang W; Liu Z; Lin X; Xue R; Zhang S; Dong L
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
    Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single cell analyses reveal the PD-1 blockade response-related immune features in hepatocellular carcinoma.
    Li Y; Li F; Xu L; Shi X; Xue H; Liu J; Bai S; Wu Y; Yang Z; Xue F; Xia Y; Dong H; Shen F; Wang K
    Theranostics; 2024; 14(9):3526-3547. PubMed ID: 38948071
    [No Abstract]   [Full Text] [Related]  

  • 4. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
    Weng J; Wang Z; Hu Z; Xu W; Sun JL; Wang F; Zhou Q; Liu S; Xu M; Xu M; Gao D; Shen YH; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
    Cancer Res; 2024 Jun; 84(11):1817-1833. PubMed ID: 38484085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatics Analysis Identifies
    Guo S; Yang Q
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):39. PubMed ID: 38287833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma.
    Wang X; Zhang Q; Zhou J; Xiao Z; Liu J; Deng S; Hong X; Huang W; Cai M; Guo Y; Huang J; Wang Y; Lin L; Zhu K
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36813307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S100A9
    Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
    J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
    Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
    J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
    Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
    J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
    J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
    Ng HHM; Lee RY; Goh S; Tay ISY; Lim X; Lee B; Chew V; Li H; Tan B; Lim S; Lim JCT; Au B; Loh JJH; Saraf S; Connolly JE; Loh T; Leow WQ; Lee JJX; Toh HC; Malavasi F; Lee SY; Chow P; Newell EW; Choo SP; Tai D; Yeong J; Lim TKH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma.
    Lu JC; Zhang PF; Huang XY; Guo XJ; Gao C; Zeng HY; Zheng YM; Wang SW; Cai JB; Sun QM; Shi YH; Zhou J; Ke AW; Shi GM; Fan J
    J Hematol Oncol; 2021 Nov; 14(1):200. PubMed ID: 34838121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of single-cell and bulk RNA sequencing reveals pro-fibrotic PLA2G7
    Wang J; Jiang M; Xiong A; Zhang L; Luo L; Liu Y; Liu S; Ran Q; Wu D; Xiong Y; He X; Leung EL; Li G
    Pharmacol Res; 2022 Aug; 182():106286. PubMed ID: 35662628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of SLFN11 Deficiency-Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti-PD-1 Therapy Efficacy in Hepatocellular Carcinoma.
    Zhou C; Weng J; Liu C; Liu S; Hu Z; Xie X; Gao D; Zhou Q; Sun J; Xu R; Li H; Shen Y; Yi Y; Shi Y; Sheng X; Dong Q; Hung MC; Ren N
    Gastroenterology; 2023 Jun; 164(7):1261-1278. PubMed ID: 36863689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing responsive and refractory orthotopic mouse models of hepatocellular carcinoma in cancer immunotherapy.
    Hage C; Hoves S; Ashoff M; Schandl V; Hört S; Rieder N; Heichinger C; Berrera M; Ries CH; Kiessling F; Pöschinger T
    PLoS One; 2019; 14(7):e0219517. PubMed ID: 31291357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.